Human papilloma virus vaccination in Nepal: An initial experience

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 3, 2010, Pages 615-617

  Singh, Yogendra ^a   Shah, Aarti ^a   Singh, Meeta ^a   Verma, Sheela ^a   Shrestha, Bhakta Man ^a   Vaidya, Prabhu ^a   Nakarmi, Radha Pyari ^a   Shrestha, Surendra B B ^a  

^a TRIBHUVAN UNIVERSITY TEACHING HOSPITAL   (Nepal)

Author keywords

Acceptability; Cervical cancer; Feasibility; HPV vaccine; Side effects

Indexed keywords

EID: 78650692416     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Agorastos T, Chatzigeorgious K, Brotherton JM, et al (2009). Safety of human papillomavirus (HPV) vaccines: A review of the international experiences so far. Vaccine, 27, 7270-81.
2. Fazekas KJ, Brewer NT, Smith JS (2008). HPV vaccine acceptability in rural, southern area. J Womens Hlth, 17, 539-48.
3. GSK (2007). HPV Vaccine Physicians Tracking Study-Wave 6, 4th Post-Gardasil Launch Report for Glaxo Smith Kline.
4. Herzog TJ, Huh WK, Downs LS, et al (2008). Initial lessons learned in HPV vaccination. Gyencol Oncol, 109, 4-11.
5. Ljubojević S (2006). The human papillomavirus vaccines. Acta Dermatovenerol Croat, 14, 208.
6. Mandic A, Vujkov T (2007). Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol, 15, 197-200.
7. Pradhananga KK, Baral M, Shrestha BM (2009). Multiinstitution hospital-based cancer incidence data for Nepal: an initial report. Asian Pac J Cancer Prev, 10, 259-62.
8. Prasai S (2008). Human Papilloma Virus vaccination: Should it be mandatory? JNMA J Nepal Med Assoc, 47, 267-71.
9. Preventing Cervical Cancer_The HPV Vaccination (online). (2007) (cited 2007 Nov 13); available from: URL: http://whqlidoc.who.int/hq/2007/WHO_IVB_07_05_eng.pdf.
10. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (2006). (cited 2007 Nov 19) available from: URL: http://www.merk.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
11. Rambout L, Hopkins L, Hutton B, et al (2007). Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ, 177, 469-79.
12. Sankaranarayana R, Bhatla N, Gravitt PE, et al (2008). Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine, 26, 43-52.
13. Study Estimates Overall HPV Prevalence in US Women (online). (2007) (cited 2007 Dec 4); available from: URL:http://www.cancer.gov/cancertopics/hpv-prevalence0307.
14. Ulanova M, Tarkowski A, Hahn-Zoric M, et al (2001). The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun, 69, 1151-9.
15. Woodman CB, Collins S, Winter H, et al (2001). Natural history of cervical human papillomavirus infection in young women. A longitudinal cohort study. Lancet, 357, 1831-6.
16. Woodman CB, Collins SI, Young LS (2007). The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer, 7, 11-22.
17. Zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-50.